GlassScriptPhysician profile
David D Shin
NPI 1811194947
$44,480.74
in general payments reported to CMS, 2019-2025
31 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,705 · 2020: $814 · 2021: $731 · 2022: $12K · 2023: $20K · 2024: $864 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $3,510 · Food and Beverage: $2,772 · Honoraria: $1,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,250.00 |
| Travel and Lodging | $3,509.54 |
| Food and Beverage | $2,771.78 |
| Honoraria | $1,850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28,235.69 | 2019-2023 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $3,685.32 | 2019-2023 | Calquence |
| Pharmacosmos Therapeutics INC. | $3,269.96 | 2023-2024 | Monoferric, Cosela |
| Pfizer INC. | $3,115.92 | 2019-2024 | |
| Amgen INC. | $1,650.00 | 2019 | |
| Gilead Sciences, INC. | $471.35 | 2019-2024 | Trodelvy |
| Seagen INC. | $361.90 | 2021-2023 | Tukysa |
| Genentech USA, INC. | $360.88 | 2019-2024 | Tecentriq |
| Regeneron Pharmaceuticals, INC. | $350.00 | 2025 | Lynozyfic |
| Takeda Pharmaceuticals U.S.A., INC. | $348.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $282.28 | 2020-2024 | |
| Janssen Biotech, INC. | $281.53 | 2020-2024 | Carvykti |
| Karyopharm Therapeutics INC. | $254.70 | 2022-2023 | Xpovio |
| Alexion Pharmaceuticals, INC. | $246.73 | 2019-2020 | |
| Taiho Oncology, INC. | $230.12 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $226.52 | 2023-2024 | Libtayo |
| Sobi, INC | $167.27 | 2024 | |
| Daiichi Sankyo INC. | $161.12 | 2020 | |
| Medtronic USA, INC. | $132.74 | 2019 | |
| Clovis Oncology, INC. | $124.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.61 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $121.97 | 2019 | |
| Genzyme Corporation | $66.00 | 2024 | |
| Beigene USA, INC. | $46.81 | 2021 | |
| Exelixis INC. | $41.91 | 2020 | |
| Blueprint Medicines Corporation | $32.57 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.88 | 2024 | Opdualag |
| Tactile Systems Technology INC | $18.92 | 2024 | Flexitouch Plus, Entre Plus |
| United Therapeutics Corporation | $18.01 | 2024 | Orenitram |
| Abbvie INC. | $16.31 | 2025 | |
| Incyte Corporation | $15.46 | 2024 | Monjuvi, Pemazyre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.